Anti-VEGF drugs: evidence for effectiveness

Article English OPEN
Evans, Jennifer ; Virgili, Gianni (2014)
  • Publisher: International Centre for Eye Health
  • Journal: Community Eye Health, volume 27, issue 87, pages 48-48 (issn: 0953-6833, eissn: 1993-7288)
  • Related identifiers: pmc: PMC4322740
  • Subject: RE1-994 | Evidence | Diagnosis and treatment | Ophthalmology | Diabetic retinopathy
    mesheuropmc: genetic structures

Anti-vascular endothelial growth factors (anti-VEGF) are targeted biological drugs (e.g. monoclonal antibodies) that prevent the growth of new vessels by inhibiting VEGF. VEGF is a cytokine (cell-signalling protein) that promotes the growth of, and leakage from, new ves... View more
  • References (3)

    1 Solomon SD Lindsley K Vedula SS Krzystolik MG Hawkins BS Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.The Cochrane database of systematic reviews 2014;8:CD005139 10.1002/14651858. CD005139.pub3[published Online First Epub Date].

    2 Virgili G Parravano M Menchini F Brunetti M Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.The Cochrane database of systematic reviews 2012;12:CD007419 10.1002/14651858.CD007419.pub3[published Online First Epub Date].

    3 Moja L Lucenteforte E Kwag KH, et al. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration.The Cochrane database of systematic reviews 2014;9:CD011230 10.1002/14651858.CD011230.pub2[published Online First Epub Date]

  • Metrics
    No metrics available
Share - Bookmark